Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203320
Status:
COMPLETED
Last Update Posted:
2006-04-24
First Post:
2005-09-12
Brief Title:
TNF-Alpha Inhibition for Treatment of Alzheimers Disease
Sponsor:
Tobinick Edward Lewis MD
Organization:
Tobinick Edward Lewis MD
Study Overview
Official Title:
Etanercept for Alzheimers-Type Memory Loss Pilot Study II
Status:
COMPLETED
Status Verified Date:
2006-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is widely believed that inflammation contributes to the pathogenesis of AD TNF has been implicated in both AD and neurological inflammation Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD
Detailed Description:
Etanercept a biologic anti-TNF fusion protein will be administered weekly or biweekly by perispinal injection to a maximum of 30 study subjects for a period of one year with serial testing of cognition and function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None